留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

Th2相关炎症因子在湿疹发病中的作用机制

朱聪聪,  潘会君,  朱全刚

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(1): 9-13
朱聪聪, 潘会君, 朱全刚. Th2相关炎症因子在湿疹发病中的作用机制[J]. 药学实践与服务, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
引用本文: 朱聪聪, 潘会君, 朱全刚. Th2相关炎症因子在湿疹发病中的作用机制[J]. 药学实践与服务, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
shu
ZHU Congcong, PAN Huijun, ZHU Quangang. Mechanism of Th2 related inflammatory factors in the pathogenesis of eczema[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
Citation: ZHU Congcong, PAN Huijun, ZHU Quangang. Mechanism of Th2 related inflammatory factors in the pathogenesis of eczema[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
shu

Th2相关炎症因子在湿疹发病中的作用机制

doi: 10.3969/j.issn.1006-0111.2019.01.003
  • 1.

    上海中医药大学附属岳阳中西医结合医院药学研究室, 上海 200437;上海市皮肤病医院药剂科, 上海 200443

  • 2.

    上海市皮肤病医院药剂科, 上海 200443

基金项目: 上海市科委资助项目（17401901800）

Mechanism of Th2 related inflammatory factors in the pathogenesis of eczema

  • 1.

    Department of Pharmacy Laboratory, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China;Department of Pharmacy, Shanghai Dermatology Hospital, Shanghai 200443, China

  • 2.

    Department of Pharmacy, Shanghai Dermatology Hospital, Shanghai 200443, China

  • 摘要: 湿疹是临床常见的炎症性皮肤病，具有剧烈瘙痒、反复发作等特点。其病因复杂，包括多种内、外因素相互作用。主要发病机制与Th2免疫应答失衡有关，相关的炎症因子更是发挥十分重要的作用。上皮衍生因子胸腺基质淋巴细胞生成素以及白介素-33（IL-33）能够引发Th2免疫失衡，促进IL-4、IL-5、IL-13等炎症因子分泌，后者进一步诱导嗜酸性粒细胞增多、IgE生成。综述Th2相关炎症因子在湿疹发病中的作用机制，对湿疹治疗具有重要意义。
    Abstract: Eczema is a common clinical inflammatory skin disease characterized by severe itching and recurrent attacks.Its etiology is complex, including a variety of internal and external factors.The main mechanism is related to the imbalance of Th2 immune response, and related inflammatory factors play an important role.Epithelial-derived factor like thymic stromal lymphopoietin and interleukin-33 could trigger Th2 immune imbalance and promote the secretion of type inflammatory factors such as interleukin-4, interleukin-5, and interleukin-13.These inflammatory factors will further induce eosinophilic granulocytosis and IgE formation.In this paper, the research progress of mechanism of type 2 related inflammatory factors in eczema were reviewed, which provided the great significance for treatment.
  • [1] DECKERS I A,MCLEAN S,LINSSEN S,et al.Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010:a systematic review of epidemiological studies[J].PLoS ONE,2012,7(7):e39803.
    [2] WEIDINGER S,NOVAK N.Atopic dermatitis[J].Lancet,2016,387(10023):1109-1122.
    [3] EYERICH K,NOVAK N.Immunology of atopic eczema:overcoming the Th1/Th2 paradigm.[J].Allergy,2013,68(8):974-982.
    [4] ESAKI H,BRUNNER P M,RENERT-YUVAL Y,et al.Early-onset pediatric atopic dermatitis is Th2 but also Th17 polarized in skin[J].J Allergy Clin Immunol,2016,138(6):1639-1651.
    [5] EYERICH K,EYERICH S.Th22 cells in allergic disease[J].Allergo J Int,2015,24(1):1-7.
    [6] LIU Y J,SOUMELIS V,WATANABE N,et al.TSLP:an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation[J].Annu Rev Immunol,2007,25:193-219.
    [7] SCHMITZ J,OWYANG A,OLDHAM E,et al.IL-33,an Interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity,2005,23(5):479-490.
    [8] HAYAKAWA H,HAYAKAWA M,KUME A,et al.Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation[J]. J Biol Chem,2007,282(36):26369-26380.
    [9] TAKAHASHI N,SUGAYA M,SUGA H,et al.Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous t-cell lymphoma[J].Cancer Res,2016,76(21):6241-6252.
    [10] DOLGIN E.First eczema biologic debuts but price could restrict use[J].Nat Biotechnol,2017,35(5):391-392.
    [11] WANG X,JIANG X,YU X,et al.Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions[J].J Cell Mol Med,2017,21(11):2926-2936.
    [12] CAYROL C,GIRARD J P.Interleukin-33(IL-33):A nuclear cytokine from the IL-1 family[J]. Nat Immunol,2018,281(1):154-168.
    [13] CAYROL C,DUVAL A,SCHMITT P,et al.Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33[J].Nat Immunol,2018,19(4):375-385.
    [14] Ding W,Zou G L,Zhang W,et al.Interleukin-33:its emerging role in allergic diseases[J].Molecules,2018,23(7):1665.
    [15] CHEN W Y,TSAI T H,YANG J L,et al.Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases[J].Cell Physiol Biochem,2018,49(1):349-358.
    [16] DU H Y,FU H Y,LI D N,et al.The expression and regulation of interleukin-33 in human epidermal keratinocytes:a new mediator of atopic dermatitis and its possible signaling pathway[J].J Interferon Cytokine Res,2016,36(9):552-562.
    [17] RYU W I,LEE H,BAE H C et al.IL-33 down-regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes[J].J Dermatol Sci,2016,82(2):131-134.
    [18] DE SALVO C,,WANG X M,PASTORELLI L et al.IL-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis[J].Am J Pathol,2016,186(4):885-898.
    [19] LI C,MAILLET I,MACKOWIAK C,et al.Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells[J].Cell Death Dis,2017,8(4):e2735.
    [20] PENG G,MU Z,CUI L,et al.Anti-IL-33 antibody has a therapeutic effect in an atopic dermatitis murine model induced by 2,4-dinitrochlorobenzene[J].Inflammation,2018,41(1):154-163.
    [21] JOHANSSON K,MALMHALL C,RAMOS-RAMÍREZ P,et al.Bone marrow type 2 innate lymphoid cells:a local source of interleukin-5 in interleukin-33-driven eosinophilia[J].Immunology,2018,153(2):268-278.
    [22] CAMELO A,ROSIGNOLI G,OHNE Y,et al.IL-33,IL-25,and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells[J].Blood Adv,2017,1(10):577-589.
    [23] XU M,DONG C.IL-25 in allergic inflammation[J].Immunol Rev,2017,278(1):185-191.
    [24] GANDHI N A,BENNETT B L,GRAHAM N M,et al.Targeting key proximal drivers of type 2 inflammation in disease[J].Nat Rev Drug Discov,2016,15(1):35-50.
    [25] ROBINSON M J,PROUT M,MEARNS H,et al.IL-4 haploinsufficiency specifically impairs IgE responses against allergens in mice[J].J Immunol,2017,198(5):1815-1822.
    [26] HEIL P M,MAURER D,KLEIN B,et al.Omalizumab therapy in atopic dermatitis:depletion of IgE does not improve the clinical course-a randomized,placebo-controlled and double blind pilot study[J].JDDG,2010,8(12):990-998.
    [27] OLDHOFF J M,DARSOW U,WERFEL T,et al.Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis[J].Allergy,2015,60(5):693-696.
    [28] ORTEGA H G,LIU MC,PAVORD I D,et al.Mepolizumab treatment in patients with severe eosinophilic asthma[J].New Engl J Med,2014,371(13):1198-1207..
    [29] CHANG H Y,NADEAU K C.IL-4Rα Inhibitor for Atopic Disease[J].Cell,2017,170(2):222.
    [30] THOMSON J,WERNHAM A G H,WILLIAMS H C.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS):a critical appraisal[J].Br J Dermatol,2018,178(4):897-902.
    [31] SZEGEDI K,VAN LIER A,RES P C,et al.House dust mite allergens Der f and Der p induce IL-31 production by blood-derived T cells from atopic dermatitis patients[J].Exp Dermatol,2018,27(4):393-395.
    [32] LEE M Y,SHIN E,KIM H et al.Interleukin-31,Interleukin-31RA,and OSMR expression levels in post-burn hypertrophic scars[J].J Pathol Transl Med,2018,52(5):307-313.
    [33] RAAP U,WICHMANN K,BRUDER M,et al.Correlation of IL-31 serum levels with severity of atopic dermatitis.[J].J Allergy Clin Immunol,2008,122(2):421-423.
    [34] NEIS M M,PETERS B,DREUW A,et al.Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and [KG3*9]allergic contact dermatitis[J].J Allergy Clin Immunol,2006,118(4):930-937.
    [35] CEVIKBAS F,WANG X,AKIYAMA T,et al.A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch:Involvement of TRPV1 and TRPA1[J].J Allergy Clin Immunol,2014,133(2):448-460.
    [36] ANDOH T,HARADA A,KURAISHI Y.Involvement of Leukotriene B4 released from keratinocytes in itch-associated response to intradermal interleukin-31 in mice[J].Acta Derm Venereol,2017,97(8):922-927.
    [37] NEMOTO O,FURUE M,NAKAGAWA H,et al.The first trial of CIM331,a humanized antihuman interleukin-31 receptor A antibody,in healthy volunteers and patients with atopic dermatitis to evaluate safety,tolerability and pharmacokinetics of a single dose in a randomized,double-blind,placebo-controlled study[J].Br J Dermatol,2016,174(2):296-304.
    [38] STANDER S,STEINHOFF M.Pathophysiology of pruritus in atopic dermatitis:an overview[J].Exp Dermatol,2002,11(1):12-24.
    [39] BAHALI A G,ONSUN N,SU O,et al.The relationship between pruritus and clinical variables in patients with psoriasis[J].An Bras Dermatol,2017,92(4):470-473.
    [40] ZEIDLER C,TSIANAKAS A,PEREIRA M,et al.Chronic prurigo of nodular type:a review[J].Acta Derm Venereol,2018,98(2):173-179.
    [41] KABASHIMA K,FURUE M,HANIFIN J M et al.Nemolizumab in patients with moderate-to-severe atopic dermatitis:Randomized,phase Ⅱ,long-term extension study[J].J Allergy Clin Immunol,2018,142(4):1121-1130.
  • [1] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [2] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [3] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [4] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [5] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [6] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [7] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [8] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [9] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [10] 李丹, 戴贤春, 王芳珍, 陈奕含, 杨萍, 刘继勇.  HPLC-MS/MS测定当归六黄汤中4种不同成分的含量 . 药学实践与服务, 2024, 42(6): 248-252, 266. doi: 10.12206/j.issn.2097-2024.202305007
    [11] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
    [12] 陈春娟, 郑志新, 李骊.  平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  5778
  • HTML全文浏览量:  478
  • PDF下载量:  380
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-28
  • 修回日期:  2018-11-20

Th2相关炎症因子在湿疹发病中的作用机制

doi: 10.3969/j.issn.1006-0111.2019.01.003
  • 1. 上海中医药大学附属岳阳中西医结合医院药学研究室, 上海 200437;上海市皮肤病医院药剂科, 上海 200443
  • 2. 上海市皮肤病医院药剂科, 上海 200443
    • 基金项目:  上海市科委资助项目（17401901800）
  • 收稿日期: 2018-09-28
  • 修回日期: 2018-11-20

摘要: 湿疹是临床常见的炎症性皮肤病，具有剧烈瘙痒、反复发作等特点。其病因复杂，包括多种内、外因素相互作用。主要发病机制与Th2免疫应答失衡有关，相关的炎症因子更是发挥十分重要的作用。上皮衍生因子胸腺基质淋巴细胞生成素以及白介素-33（IL-33）能够引发Th2免疫失衡，促进IL-4、IL-5、IL-13等炎症因子分泌，后者进一步诱导嗜酸性粒细胞增多、IgE生成。综述Th2相关炎症因子在湿疹发病中的作用机制，对湿疹治疗具有重要意义。

English Abstract

朱聪聪, 潘会君, 朱全刚. Th2相关炎症因子在湿疹发病中的作用机制[J]. 药学实践与服务, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
引用本文: 朱聪聪, 潘会君, 朱全刚. Th2相关炎症因子在湿疹发病中的作用机制[J]. 药学实践与服务, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
shu
ZHU Congcong, PAN Huijun, ZHU Quangang. Mechanism of Th2 related inflammatory factors in the pathogenesis of eczema[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
Citation: ZHU Congcong, PAN Huijun, ZHU Quangang. Mechanism of Th2 related inflammatory factors in the pathogenesis of eczema[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 9-13. doi: 10.3969/j.issn.1006-0111.2019.01.003
shu

    全文HTML

参考文献 (41)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计